Annotation Detail

Information

Associated Genes: BRAF
Associated Variants: BRAF V600
BRAF V600
Associated Disease: colorectal cancer
Source Database: CIViC Evidence
Description: A randomized clinical trial was done with metastatic colorectal cancer (mCRC) patients (50 in the control group, 49 in the experimental group) with BRAF V600 mutations and RAS wild type that were enrolled from December 2014 to April 2016. The patients were randomized into groups with irinotecan and cetuximab with vemurafenib (VIC group) or without (IC group). The VIC group showed an improvement of progression of free survival (HR 0.42, 95% CI: 0.26 to 0.66, p < 0.001) with a median value of 4.4 months compared to 2.0 months for the IC group. In addition, for the VIC group, there was a 16% drug response rate while the IC group had a 4% drug response rate (p-value = 0.08). Some grade 3/4 adverse events were higher in the experimental arm, and skin toxicity and fatigue showed no increase.
Variant Origin: somatic
Variant Origin: Somatic
Evidence URL: https://civic.genome.wustl.edu/links/evidence_items/7355
Gene URL: https://civic.genome.wustl.edu/links/genes/5
Variant URL: https://civic.genome.wustl.edu/links/variants/17
Rating: 3
Evidence Type: Predictive
Disease: Colorectal Cancer
Evidence Direction: Supports
Drug: Vemurafenib,Cetuximab,Irinotecan
Evidence Level: B
Clinical Significance: Sensitivity/Response

Drugs